GSK Announces Plans To Pay $3.3 Billion To Purchase Affinivax

GSK Announces Plans To Pay $3.3 Billion To Purchase Affinivax

To enhance its vaccine pipeline, which is a top focus as the British pharmaceutical firm prepares to spin off its consumer division, GSK intends to pay up to $3.3 billion for privately held biotech startup Affinivax.

GSK, the largest vaccine manufacturer in the world based on sales, has been under pressure to strengthen its pipeline.

According to the firm, Affinivax, a U.S.-based company, is developing next-generation vaccines, the most crucial of which are for pneumococcal illnesses like pneumonia, meningitis, and sinusitis.

The 2022 prognosis and medium-term objectives of the London-listed corporation were also reiterated on Tuesday. Affinivax will probably receive $2.1 billion from GSK up front, with potential development milestone payments.

Tuesday saw a partial recovery in Asian market prices as signs that China’s economic troubles may be improving due to a reduction in COVID-related tensions began to surface.

The 19 curbs outweighed investor worries about a global inflation surge. It indicated a willingness for additional acquisitions last month after investing $1.9 billion to strengthen its cancer division with Sierra Oncology (SRRA).

The region’s optimism was also boosted by news of Beijing’s policy shift support, which includes cash incentives for hiring graduates and assistance with overseas listings for online enterprises.

Due to Europe’s promise to cut back on its imports of Russian oil, oil prices have risen to their highest levels in two months, heightening dangers and concerns.

As investors prepared for a flurry of interest rate hikes that would bring the benchmark rate closer to 3 percent, Fed funds futures fell significantly in Asia. Hopes that the US Federal Reserve may take a break after its recent rate hikes were further dashed by the governor’s hawkish remarks.

Read our latest blog…

The trade-sensitive New Zealand dollar fell from a three-week high on strong domestic data and contentment that China’s downturn appeared to be abating, while the AUD found support.

The official PMI for May in China showed that manufacturing activity was still declining, albeit at a little slower rate than in April, which helped lift spirits.

This was sufficient to restore cautious optimism in the financial markets, along with official statements of support and a decline in Shanghai lockdowns.

More at:

Get a Callback

A trusted broker will contact you today.

Trading View

Top Brokers